218 related articles for article (PubMed ID: 34018172)
1. Tumefactive Demyelinating Lesions in a Patient with Multiple Sclerosis Developed two Days after the Injection of Rituximab.
Moghadasi AN
Acta Neurol Taiwan; 2020 Dec; 29(4)():124-127. PubMed ID: 34018172
[TBL] [Abstract][Full Text] [Related]
2. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
3. Tumefactive multiple sclerosis (TMS): A case series of this challenging variant of MS.
Villarreal JV; Abraham MJ; Acevedo JAG; Rai PK; Thottempudi N; Fang X; Gogia B
Mult Scler Relat Disord; 2021 Feb; 48():102699. PubMed ID: 33373797
[TBL] [Abstract][Full Text] [Related]
4. [A case of multiple sclerosis with a tumefactive lesion during long-term treatment with fingolimod, leading to decompressive craniotomy].
Shiraishi W; Miyata T; Matsuyoshi A; Yamada Y; Hatano T; Hashimoto T
Rinsho Shinkeigaku; 2023 Jan; 63(1):37-44. PubMed ID: 36567105
[TBL] [Abstract][Full Text] [Related]
5. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
[TBL] [Abstract][Full Text] [Related]
6. A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome.
Gnanapavan S; Jaunmuktane Z; Baruteau KP; Gnanasambandam S; Schmierer K
BMC Neurol; 2014 Apr; 14():68. PubMed ID: 24694183
[TBL] [Abstract][Full Text] [Related]
7. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
[TBL] [Abstract][Full Text] [Related]
8. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
Jander S; Turowski B; Kieseier BC; Hartung HP
Mult Scler; 2012 Nov; 18(11):1650-2. PubMed ID: 23100527
[TBL] [Abstract][Full Text] [Related]
9. Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.
Ikeda KM; Lee DH; Fraser JA; Mirsattari S; Morrow SA
Int J MS Care; 2015; 17(5):231-5. PubMed ID: 26472944
[TBL] [Abstract][Full Text] [Related]
10. A challenging diagnosis of late-onset tumefactive multiple sclerosis associated to cervicodorsal syringomyelia: doubtful CT, MRI, and bioptic findings: Case report and literature review.
Conforti R; Capasso R; Galasso R; Cirillo M; Taglialatela G; Galasso L
Medicine (Baltimore); 2016 Sep; 95(36):e4585. PubMed ID: 27603348
[TBL] [Abstract][Full Text] [Related]
11. Balo's concentric sclerosis: An atypical demyelinating disease in pediatrics.
Arenas Vargas LE; Bedoya Morales AM; Rincón Carreño C; Espitia Segura OM; Penagos N
Mult Scler Relat Disord; 2020 Sep; 44():102198. PubMed ID: 32531753
[TBL] [Abstract][Full Text] [Related]
12. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
13. Tumefactive demyelinating lesions in a patient with multiple sclerosis receiving natalizumab.
Moghadasi AN; Baghbanian SM
Acta Neurol Belg; 2019 Mar; 119(1):137-139. PubMed ID: 29876751
[No Abstract] [Full Text] [Related]
14.
Huhn K; Mennecke A; Linz P; Tschunko F; Kästle N; Nagel AM; Uder M; Dörfler A; Linker RA; Engelhorn T
J Neurol Sci; 2017 Aug; 379():163-166. PubMed ID: 28716233
[TBL] [Abstract][Full Text] [Related]
15. Pediatric tumefactive multiple sclerosis case (with baló-like lesions), diagnostic and treatment challenges.
Kamari C; Galanakis E; Raissaki M; Briassoulis G; Vlachaki G; Vorgia P
Neurol Sci; 2023 Jan; 44(1):343-345. PubMed ID: 36171523
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of [
Hashimoto S; Inaji M; Nariai T; Kobayashi D; Sanjo N; Yokota T; Ishii K; Taketoshi M
Neurol Med Chir (Tokyo); 2019 May; 59(5):176-183. PubMed ID: 30996153
[TBL] [Abstract][Full Text] [Related]
17. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
Jeung L; Smits LMG; Hoogervorst ELJ; van Oosten BW; Frequin STFM
Mult Scler Relat Disord; 2020 May; 40():101978. PubMed ID: 32062445
[TBL] [Abstract][Full Text] [Related]
18. Tumefactive multiple sclerosis in Taiwan.
Kuan YC; Wang KC; Yuan WH; Tsai CP
PLoS One; 2013; 8(7):e69919. PubMed ID: 23875010
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in Tumefactive demyelinating lesions: A retrospective study.
Plowman RS; Varma H
J Neurol Sci; 2021 Sep; 428():117591. PubMed ID: 34333380
[TBL] [Abstract][Full Text] [Related]
20. Multiple Large Tumefactive MS Plaques in a Young Man: A Diagnostic Enigma and Therapeutic Challenge.
Kalanie H; Harandi AA; Bakhshandehpour R; Heidari D
Case Rep Radiol; 2012; 2012():363705. PubMed ID: 22844629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
